Celgene Revlimid MDS filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celgene is requesting a priority review for its Revlimid (lenalidomide) NDA for treatment of transfusion-dependent patients with myelodysplastic syndromes with a 5q deletion chromosomal abnormality. A rolling submission was completed April 8, the company said. The submission is based on a Phase II trial in patients with the 5q deletion abnormality. Revlimid has fast track designation for MDS as well as multiple myeloma. The firm's Thalomid (thalidomide) sNDA for use in multiple myeloma has been "approvable" since October 2004...
You may also be interested in...
Thalomid myeloma sNDA “approvable”
Celgene's immunomodulatory drug Thalomid (thalidomide) has received a second "approvable" letter for treatment of multiple myeloma, the firm announces Nov. 15. FDA appears to be suggesting limiting the indication to newly diagnosed patients: "FDA has requested revised product labeling with the specific indication of newly diagnosed multiple myeloma and updated safety information, as well as some additional patient information to finalize its review," Celgene reports. The myeloma sNDA was originally submitted in December 2003; an initial approvable letter was issued in October 2004 (Pharmaceutical Approvals Monthly April 2005, In Brief). Thalomid is currently approved for treatment of erythema nodosum leprosum...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.